Aurora Kinase
Aurora kinases are a family of serine-threonine kinases of three highly homologous members, including aurora A kinase, aurora B kinase and aurora C kinase, which are responsible for chromosome assembly and segregation during mitosis. Aurora kinases are characterized by two domains: a regulatory domain in the NH2 terminus and a catalytic domain in the COOH terminus, in which an A-Box and a D-Box found correspondingly in each domain are responsible for protein degradation. Aurora A kinase plays an important role in centrosome function and duplication, mitotic entry and bipolar spindle assembly; while Aurora B kinase is the catalytic component of the chromosomal passenger complex regulating the accurate segregation of the chromatids at mitosis, histone modification and cytokinesis. Aurora C kinase is less studied and expressed restrictedly in the testes.
Products for Aurora Kinase
- Cat.No. Product Name Information
-
GC35216
AAPK-25
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM.
-
GC62433
AKI603
AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC50 of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells.
-
GC13198
AMG-900
A selective pan-Aurora kinase inhibitor
-
GC10638
AT9283
A broad spectrum kinase inhibitor
-
GC72964
Aurkin A
Aurkin A is an allosteric inhibitor for the interaction between Aurora A Kinase (also known also Aurka) and TPX2, through targeting the TPX2 binding sites with Kd of 3.77 μM.
-
GC13332
Aurora A Inhibitor I
A potent and selective inhibitor of Aurora A kinase
-
GC33379
Aurora B inhibitor 1
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
-
GC38441
Aurora Kinase Inhibitor 3
A potent inhibitor of Aurora A kinase
-
GC40667
Aurora Kinase Inhibitor II
4-(4-Benzamidoanilino)-6,7-dimethoxyquinazoline
Aurora Kinase Inhibitor II is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively. -
GC15711
Aurora Kinase Inhibitor III
Aurora Kinase Inhibitor III is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM, and weakly inhibits EGFR with an IC50 of >10 μM.
-
GC67899
Aurora kinase inhibitor-8
-
GC73375
Aurora Kinases-IN-3
Aurora Kinases-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB.
-
GC48971
AZD 1152 (hydrochloride)
Barasertib
A prodrug for a potent Aurora B inhibitor -
GC14709
AZD1152
-
GC14955
Barasertib (AZD1152-HQPA)
BarasertibHQPA
A selective Aurora kinase B inhibitor -
GC17828
BI-847325
dual inhibitor of MEK and Aurora kinases
-
GC42933
Binucleine 2
Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki = 0.36 μM), a kinase involved in cell division.
-
GC11310
CCT129202
An Aurora kinase inhibitor
-
GC14566
CCT137690
An inhibitor of Aurora kinases and FLT3
-
GC19092
CCT241736
CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM).
-
GC48982
CD532
An inhibitor of Aurora A kinase activity and the Aurora A-N-Myc protein-protein interaction
-
GC62189
CD532 hydrochloride
CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer.
-
GC35651
Cenisertib
AS-703569; R-763
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. -
GC62145
Chiauranib
CS2164
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects. -
GC15106
CYC116
A potent Aurora kinase inhibitor
-
GC15217
Danusertib (PHA-739358)
PHA-739358
A pan-Aurora kinase and Abl inhibitor -
GC68147
dAURK-4 hydrochloride
-
GC74000
DBPR728
DBPR728 is an acyl prodrug of 6K465 that carries fewer drogen bond donors.
-
GC73753
EGFR/AURKB-IN-1
EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively.
-
GC16519
ENMD-2076
A multi-kinase inhibitor
-
GC12145
ENMD-2076 L-(+)-Tartaric acid
-
GC69068
ENMD-2076 Tartrate
ENMD-2076 Tartrate is a multi-target kinase inhibitor that inhibits Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src and PDGFRα with IC50 values of 1.86, 14, 58.2, 15.9, 92.7, 70.8 ,20.2 and 56.4 nM respectively.
-
GC10008
GSK1070916
GSK-1070916A
A potent inhibitor of Aurora B and C kinases -
GC17196
Hesperadin
A multi-kinase inhibitor
-
GC50050
Hesperadin hydrochloride
Potent Aurora kinase B inhibitor
-
GC34159
Ilorasertib (ABT-348)
ABT-348
Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). -
GC38519
Ilorasertib hydrochloride
ABT-348 hydrochloride
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). -
GC73744
JAB-2485
JAB-2485 is a potent and selective Aurora kinase A (AURKA) inhibitor, with an IC50 of 0.33 nM.
-
GC12612
JNJ-7706621
JNJ7706621, JNJ 7706621
A dual inhibitor of CDKs and Aurora kinases -
GC14592
KW 2449
A multi-kinase inhibitor
-
GC33057
LY3295668 (AK-01)
AK-01
LY3295668 (AK-01) (AK-01) is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively. -
GC17162
MK-5108 (VX-689)
VX-689
A potent inhibitor of Aurora kinases -
GC10442
MK-8745
Aurora A inhibitor,potent and selective
-
GC12208
MLN8054
An inhibitor of Aurora A kinase
-
GC12690
MLN8237 (Alisertib)
Alisertib
Alisertib (MLN8237), as an investigational, orally available, selective aurora A kinase inhibitor, is usually used for the treatment of solid tumors and hematologic malignancies. -
GC34692
NU6140
A Cdk2 inhibitor
-
GC18074
PF-03814735
PF-03814735 is a potent, orally bioavailable, reversible inhibitor of both Aurora1 and Aurora2 kinases with IC50 values of 0.8nM and 5nM, respectively [1].
-
GC10479
PHA-680632
Pha 680632
An Aurora kinase inhibitor -
GC13668
Phthalazinone pyrazole
Aurora A kinase inhibitor
-
GC14651
Reversine
Reversine is a non-specific, orally active small molecule inhibitor of Aurora A kinase, Aurora B kinase and MPS1 (Monopolar Spindle 1) kinase. Reversine is often used in the study of cell differentiation and various cancer.
-
GC16614
SCH-1473759
SCH1473759;SCH 1473759
-
GC37606
SCH-1473759 hydrochloride
SCH-1473759 hydrochloride is an aurora inhibitor with IC50s of 4 and 13 nM for aurora A and B, respectively.
-
GC25940
SNS-314
SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.
-
GC13837
SNS-314 Mesylate
A pan-Aurora kinase inhibitor
-
GC17455
TAK-632
A selective pan-Raf inhibitor
-
GC11085
TAK-901
A non-selective inhibitor of Aurora kinases
-
GC62482
TAS-119
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC50 of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC50 of 95 nM). TAS-119 has potent antitumor activites.
-
GC16378
TC-A 2317 hydrochloride
Potent Aurora kinase A inhibitor (Ki = 1.2 nM compared to 101 nM for inhibition of Aurora kinase B).
-
GC70030
Tinengotinib
Tinengotinib is a regulator of one or more protein kinases, such as Aurora kinase and VEGFR kinase. Tinengotinib has the potential to study diseases mediated by these kinase abnormalities, especially cancer-related diseases (excerpt from patent WO2018108079A1).
-
GC11549
VX-680 (MK-0457,Tozasertib)
Tozasertib, VX-680
An Aurora kinase inhibitor that regulates mitosis -
GC13102
XL228
A tyrosine kinase inhibitor
-
GC14409
ZM 447439
Selective inhibitor of Aurora B kinase